Waldencast (NASDAQ:WALD) Given New $7.25 Price Target at DA Davidson

Waldencast (NASDAQ:WALD) had its target price boosted by DA Davidson from $6.50 to $7.25 in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Telsey Advisory Group dropped their price objective on Waldencast from $8.00 to $6.00 and set an outperform rating on the stock in a research note on Thursday, August 29th.

Waldencast Stock Up 14.3 %

Waldencast stock opened at $3.44 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.78 and a current ratio of 1.47. The company’s 50-day moving average is $3.17 and its 200-day moving average is $4.70. Waldencast has a fifty-two week low of $2.40 and a fifty-two week high of $12.00.

Hedge Funds Weigh In On Waldencast

Large investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new stake in shares of Waldencast during the 2nd quarter worth about $37,000. Catalina Capital Group LLC bought a new position in shares of Waldencast during the first quarter worth approximately $73,000. Cubist Systematic Strategies LLC bought a new position in shares of Waldencast during the second quarter worth approximately $85,000. Norden Group LLC acquired a new stake in Waldencast during the 1st quarter worth approximately $92,000. Finally, Simplicity Wealth LLC bought a new stake in Waldencast in the 1st quarter valued at $142,000. 41.97% of the stock is owned by institutional investors.

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.